Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate the antitumor activity, toxicity, and effectiveness of the combination of Arimidex and Zoladex in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast.
To evaluate the antitumor activity, as measured by frequency of objective response and time to progression, of combination Arimidex and Zoladex in the treatment of premenopausal women with hormone receptor [ Time Frame: every 3 months ]
To evaluate the toxicity of combination Arimidex and Zoladex in the treatment of premenopausal women with hormone receptor positive, metastatic carcinoma of the breast. [ Time Frame: every 3 months ]
To assess the effectiveness of the combination of Arimidex and Zoladex in suppression of plasma estradiol in premenopausal women with hormone receptor positive, premenopausal breast cancer. [ Time Frame: 6 months ]
Secondary Outcome Measures
Clinical benefit and survival will also be assessed as secondary endpoints. [ Time Frame: every 3 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:- Patients must have a histologically confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive.
All patients must be female and premenopausal. Premenopausal is defined as either: (1) last menstrual period within 3 months, or (2) post-hysterectomy without bilateral oophorectomy and with FSH in the premenopausal range, or, (3) if on tamoxifen within the past 3 months, a plasma estradiol in the premenopausal range.
Patients must have either positive estrogen and/or progesterone receptor determination by IHC or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen.
No prior treatment with an aromatase inhibitor or inactivator.
No prior treatment with an LH/RH agonist/antagonist.
No adjuvant chemotherapy within 6 months of study entry.
Patients must have an ECOG performance status of 0, 1, or 2.
Patients must have adequate bone marrow, hepatic, and renal function defined by the following:
Granulocytes > 1500/mm^3
Platelets > 100,000/mm^3
SGOT < 2.5x upper limit of normal
Total bilirubin < 1.5 mg/dL
Patients with central nervous system metastasis or lymphangitic pulmonary metastasis are not eligible.
Patients must not have received chemotherapy or hormonal therapy for at least 3 weeks prior to enrollment.
Patients may receive irradiation to bony sites of disease for pain control or for prevention of fracture, but the irradiated site(s) will NOT be considered evaluable for disease response.
Patients who are pregnant or lactating are ineligible. Must be using effective contraception or not be of childbearing potential.
Patients must not have had an active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years.
No active, unresolved infection.
All patients must give signed written informed consent.